Key takeaways

• Across studies, long COVID prevalence varies widely because of differing definitions, study designs, and populations.
• Global syntheses generally suggest that a measurable minority of people have symptoms lasting at least 3 months after infection—often in the single-digit percentages overall, higher after severe illness, and lower in the vaccine/Omicron era.
• In adolescents and teens, persistent symptoms occur, but controlled studies often show lower prevalence than in adults and a smaller “excess risk” compared with uninfected peers.
• Vaccination and newer variants are associated with reduced risk, though not zero risk.
• Even modest percentages translate into large numbers worldwide and can substantially affect schooling, mental health, and family life.

What is long COVID?

Long COVID (also called post-COVID condition or PASC) refers to new, returning, or ongoing health problems after the acute phase of SARS-CoV-2 infection. Definitions differ:

• WHO: symptoms that start within 3 months of infection and last at least 2 months without an alternative diagnosis.
• NICE (UK): symptoms persisting beyond 12 weeks after acute COVID-19.
• CDC (US): symptoms that persist or emerge 4+ weeks after infection.

Common manifestations include fatigue, decreased exercise tolerance, shortness of breath, neurocognitive difficulties (“brain fog”), headaches, sleep disturbance, palpitations, dysautonomia (including POTS), changes in smell or taste, and mood symptoms such as anxiety or depression. Severity ranges from mild and intermittent to disabling.

How common is long COVID globally?

Recent overviews and meta-analyses reported by outlets such as CIDRAP emphasize that prevalence estimates depend on who is studied, how long after infection they are assessed, which symptoms are counted, and whether a comparison group is used.

Broad patterns across large studies include:

• Overall population: Many pooled estimates fall in the single-digit percentages (for example, roughly 5% to 10%) for people reporting symptoms at ~3 months post-infection. Earlier waves and unvaccinated groups often showed higher figures; later waves and vaccinated groups show lower ones.
• By severity of acute illness: Hospitalized or ICU-treated patients have substantially higher rates, with some cohorts reporting double-digit prevalence long after discharge.
• Duration: A significant fraction of those with long COVID improve over 6 to 12 months, but a subset report symptoms persisting beyond a year.
• Heterogeneity: Estimates vary by region and study design; low- and middle-income countries remain underrepresented, so true global burden may be mischaracterized.

Importantly, studies that include test-negative or never-infected control groups often find that some symptoms are common in the general population as well (e.g., fatigue, headaches), which can reduce the “excess risk” attributable to COVID-19 while still confirming a real, measurable impact.

What do studies show for adolescents and teens?

Adolescents can experience long COVID, but the pattern differs from adults:

• Lower average prevalence than adults: Large school- and population-based cohorts with appropriate controls often find persistent symptoms in a small proportion of teens at 3 to 6 months, with an excess risk over uninfected peers typically in the low single digits. Some earlier or uncontrolled studies reported higher rates.
• Common symptoms: Fatigue, reduced exercise tolerance, headaches, sleep problems, difficulty concentrating, dizziness, chest pain, and mood symptoms. Some teens also report autonomic symptoms (e.g., lightheadedness on standing) and prolonged recovery after exertion.
• Risk modifiers: Older adolescent age, female sex, more severe or symptomatic acute illness, asthma or other chronic conditions, and pre-existing anxiety or depression are associated with higher risk in several cohorts.
• Course over time: Many teens improve gradually, but a subset require accommodations for school attendance, activity pacing, or mental health support for months.

The bottom line from controlled studies summarized by CIDRAP and others: while most teens recover fully, long COVID is real in this age group and, because of the scale of infections, affects a meaningful number of adolescents worldwide.

Vaccination, variants, and reinfections

• Vaccination: Multiple analyses associate prior vaccination with a reduced risk of developing long COVID and with milder or shorter-lasting symptoms when it occurs. Estimated risk reduction varies by study but is consistently protective.
• Variants: Observational data suggest lower long COVID risk after Omicron-lineage infections compared with earlier variants, though risk is not eliminated.
• Reinfections: Reinfections can still lead to long COVID; cumulative risk may depend on number of infections, vaccination status, and host factors.

Why estimates differ: methods matter

Prevalence figures are highly sensitive to study design:

• Case definitions and follow-up windows: Counting symptoms at 4 weeks vs 12 weeks yields different estimates.
• Control groups: Studies without controls tend to overestimate because many symptoms are nonspecific.
• Recruitment and recall bias: Clinic-based samples and self-referred participants often have higher symptom burdens than community samples.
• Outcome measures: Checklists vs clinician adjudication vs functional limitations can produce divergent results.
• Underrepresentation: Many regions and vulnerable populations lack robust data, limiting generalizability.

Impact on health systems, schools, and families

• Healthcare: Demand for multidisciplinary clinics (primary care, pulmonary, neurology, cardiology, rehabilitation, mental health) persists, even as overall rates decline relative to early waves.
• Education: Teens with long COVID may need temporary academic accommodations, activity pacing, attendance flexibility, and return-to-activity plans similar to post-concussion approaches.
• Mental health: Symptoms and uncertainty can exacerbate anxiety and depression; integrated behavioral health support improves outcomes.
• Equity: Access to diagnosis, rehab, and school supports is uneven, underscoring the importance of clear guidance and resources.

What we still need to learn

• Standardized, age-specific definitions that balance sensitivity and specificity.
• Better data from underrepresented regions and from primary care/community settings.
• Biomarkers and phenotyping to identify subtypes and guide targeted therapies.
• Longer-term follow-up to understand recovery trajectories beyond 12–24 months.
• Randomized trials of rehabilitation strategies, autonomic dysfunction management, and pacing vs graded activity in youth.

Practical considerations for families and schools

• Validate symptoms and track them over time (sleep, activity, cognition, mood) to inform care and accommodations.
• Support return to school with flexible plans, reduced workload, rest breaks, and gradual reconditioning as tolerated.
• Address sleep, hydration, nutrition, and mental health; consider evaluation for autonomic symptoms when present.
• Keep vaccinations up to date to reduce risk of severe disease and long-term sequelae.
• Coordinate among primary care, specialists, and school personnel to avoid fragmented care.

Note: This information is educational and not a substitute for professional medical advice. Families should consult healthcare professionals for individualized guidance.

Conclusion

Reporting from CIDRAP and other evidence syntheses underscores a consistent message: long COVID remains a significant, though heterogenous, consequence of SARS-CoV-2 infection. Globally, a modest percentage of people—fewer in vaccinated and Omicron-era cohorts—experience symptoms that persist for months. In adolescents, the proportion is generally lower than in adults, especially when compared to well-matched controls, but the absolute numbers are still substantial given how many teens have been infected. Continued surveillance, equitable access to care, and practical supports in schools can mitigate the impact while research clarifies mechanisms and optimizes treatment.